{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000065","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.942077+00:00","generated_at":"2026-05-17T00:53:28.806002+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M","bullets":["Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.","Optimized profile cohort (N=35): 86% ORR, 63% CR rate, 53% 12-month PFS; median follow-up 11.8 months.","CB-011 (BCMA) dose escalation: 92% ORR, 75% CR/sCR at RDE (450M cells) in BCMA-naïve r/r MM; dose expansion by end 2025.","Planned pivotal phase 3 for vispa-cel in 2L LBCL: FDA recommends randomized controlled trial, ~250 patients, PFS primary endpoint.","Preliminary cash, equivalents, and marketable securities as of Sep 30, 2025: approximately $159.2 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000065","json":"https://secwatch.observer/filing/0001619856-25-000065.json","markdown":"https://secwatch.observer/filing/0001619856-25-000065.md","text":"https://secwatch.observer/filing/0001619856-25-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/0001619856-25-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/crbu-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:53:28.806002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}